Open Orphan seals deal that could net more than €11.6m

Dublin-listed pharma group announces contract with European biotech company

Open Orphan executive chairman Cathal Friel said the acquisition of Hvivo was reaping benefits for the company.  Photograph: Alan Betson / The Irish Times

Open Orphan executive chairman Cathal Friel said the acquisition of Hvivo was reaping benefits for the company. Photograph: Alan Betson / The Irish Times

Dublin-listed pharma services company Open Orphan has announced the signing of a new contract with a European biotech company that could yield it more than £10 million in revenue this year.

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed the Irish stock exchange of the deal for the provision of an respiratory syncytial virus (RSV) human challenge study on Friday.

Please subscribe or sign in to continue reading.
only €1 first month

Insightful opinion is just a away.